Conclusion: Is microdosing semaglutide right for you
In January 2025, PRAC began its review of medicines containing semaglutide, after noting that two recent observational studies suggested an elevated risk of patients developing NAION
The trials enrolled thousands of adults with obesity or overweight with weight-related health conditions across multiple countries and ran for 68 weeks
Zepbound is approved by the FDA as a weight loss management treatment for people with obesity or those who are overweight with at least one weight-related condition such as high blood pressure
Dinner: Tofu stir-fry (6 ounces firm tofu) with bok choy, mushrooms, snap peas, garlic, ginger, and low-sodium soy sauce over half a cup of brown rice
This medication, a GLP-1 receptor agonist, mimics the hormone GLP-1 to help regulate blood sugar levels and reduce appetite